Login to Your Account

UK's Cellzome in $1.5B Deal with GSK for Kinase Inhibitors

By Nuala Moran

Wednesday, September 10, 2008
LONDON - Anglo/German kinase specialist Cellzome Inc., sealed a deal worth a headline value of £830 million (US$1.5 billion) with GlaxoSmithKline plc for the development of kinase inhibitors in the treatment of inflammatory diseases. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription